Samsung BioEpis pitches Herceptin biosimilar as parent company hunts $2B IPO; Chiasma CEO is out
In the latest advance by a new wave of biosimilars hitting regulators on both sides of the Atlantic, Samsung Bioepis says that it has filed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
